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Introductory and Commentary

During 198$ the Cancer Committee of St. Luke’s Medical Center
oversaw the Cancer Program as a Center of Excellence. New programs
which were instituted in 198$ were the Interleukin 2/LAK Cell
Therapy for various malignancies, intraoperative radiation therapy, a
new in-house malignant glioma protocol and a new Photodynamic
Therapy Protocol for lung tumors. Efforts were made to increase the
activity through specific goals and increasing meeting frequency to
bimonthly. A major effort was to improve the awareness of the medical
staff, especially the primary care physicians, as to the services available
at St. Luke’s Medical Center for their cancer patients. Activities
included direct communication with the Primary Care Departments
through written reports, and requests that their departmental members
who function on the Cancer Committee serve as liaisons. Preliminary
efforts for planning an Early Detection and Screening Program and a
Hospice Program at St. Luke’s were begun. Mr. Greg Fecteau was
appointed as the Cancer Program Director.
Dr. Howard Lewis was appointed chairperson of a Quality Assurance
Subcommittee. During 1988 the subcommittee reviewed patients with
pancreatic cancer, bronchogenic cancer, and head and neck cancer.
The American College of Surgeons’ review focused on carcinoma of the
colon and rectum, 15% of all the U.S. malignancies, as does this
annual report. In the United States in 198$, 147,000 individuals were
diagnosed with colorectal carcinoma and 61,500 succumbed to the
disease. For the State of Wisconsin there were 3 ,100 individuals who
presented with the disease and 1,400 who died from colorectal cancer.
Recent advances in the treatment of this disease have been
incremental, and in part related to separating the treatment of colon
cancer from that of rectal cancer, due to different biological patterns.
When diagnosed early it is highly curable; however, when diagnosed
late it is highly fatal with a tendency toward distant spread, and, in
the rectal area, loco-regional recurrence. Fortunately, appropriate use of
combinations of surgery, systemic chemotherapy and radiation therapy
have led to improvements in outcome. Additionally, there is increasing
emphasis on the etiology of colorectal cancer, indicating that it may
be caused or promoted by environmental factors, especially dietary
factors that affect the enteric milieu.
Early detection procedures may lead to the recognition of more curable
patients. The following are recommendations for screening of the
general population: yearly fecal occult blood tests and sigmoidoscopy
should be done every 3-5 years beginning at age 40.
Colorectal carcinoma illustrates well the need for cooperation between
the primary care physician in educating for prevention and performing
early detection procedures, and the surgeon, radiation therapist, and
medical oncologist in treating the patient when disease is identified
and/or recurrent.
Marcia J.S. Richards, M.D.

Chairperson, Cancer Committee 19$ 8
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St. Luke’s Medical Center
Recipient Charity of
Vince Lombardi Memorial Classic
The Lombardi Board of Directors recently
approved St. Luke’s Medical Center as its
recipient charity and relocated the Vince
Lombardi Cancer Clinic to St. Luke’s Medical
Center, Milwaukee, Wisconsin. While the
Lombardi Golf Classic is a tribute to
Vince
;
one of America’s memorable sports personali
ties, its more compelling purpose is to fight
cancer, the disease that claimed Vince
Lombardi’s life.
t
Greg Fecteau
In 1971, concerned members of North Hills
Country Club in Menomonee Falls, Wisconsin, were joined by
golfers from other clubs and by Milwaukee area citizens who
shared a love and respect for Coach Lombardi. The Classic was
born. It is governed by a committee that donates time, talent and
great energy toward the goal of defeating cancer in the true
Lombardi spirit and drive for excellence.
Dedication and extra effort have made the Annual Vince
Lombardi Memorial more successful each year. To date, the
Lombardi Classic Memorial has donated $1,158,552 for cancer
research. The goal for 1990-1994 is $1,000,000! The 1990 Vince
Lombardi Memorial Classic will be held June 15 & 16, 1990.
The Finance and Revenue Committee of the Classic believe that
approximately one-half of this million dollars will be raised by the
various activities associated with the Memorial Golf Classic which
include:
. Golf Classic
North Hills Country Club
. Super Raffte
Sponsored by Sundance Photo
. Run for Daylight (run/walk)
Sponsored by Schwister Ford
Banks
and F&M
. Auction
. Corporate and individual donors
.

.

.

A comfortable, homelike atmosphere is
featured at the Vince Lombardi Cancer
Clinic.

-

-

-
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The other 50% will be funded through the BLOCKS OF
GRANITE Program. Donations are made to the Lombardi
Foundation-Trust which give Blocks of Granite participants various
financial options to meet their needs.
Many people have made major contributions of time, effort and
money to make the Lombardi Memorial Classic one of the finest
charitable events in the United States. St. Luke’s Medical Center is
honored to be affiliated with these outstanding individuals and
their fight against cancer.
St. Luke’s Medical Center is committed to excellence in oncology
through the Cancer Center of Excellence. The comprehensive
cancer team that exists here addresses all components of cancer
care, from the most experimental research trials to state-of-the-art
application of established therapy, and from earliest diagnosis to
compassionate care of the terminally ill. The Vince Lombardi
Cancer Clinic will exist within and grow with that Center of
Excellence.
As Vince Lombardi stated,
“The quality of a person’s life is in direct proportion
to their commitment to excellence,
regardless of their chosen field of endeavor.”
We believe that the key to saving the Vince Lombardi’s of the
future from untimely cancer death lies in establishing a center
that will make cancer a preventable and controllable disease in
the community of Milwaukee and the State of Wisconsin.
Greg Fecteau
Director, St. Luke’s Cancer Program
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Vmce Lombardi Memorial Classic
(continued)
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Bart Starr, chairman of the Vince
Lombardi Memorial Classic, joined
Dr. Ronald Hart, at the clinic’s
dedication, March 19, 1990.

Cant and 11eatment
for Colon Cancer

Colorectal cancer affects approximately one
person in 20 in the United States and most
western countries. It is second in incidence
and mortality only to cancer of the lung.
When diagnosed in its early stages it is highly
curable with surgical management, but unfor
tunately is often not identified until it has
spread regionally or even in some patients
presenting with distant spread.

Commentary on
Colorectal Cancer

The incidence of colon cancer
diagnosedfor the last ten
years at St. Luke’s Medical
Center has remained stable.

As in many other malignancies early detection
results in the greatest chance of cure with the
American Cancer Society recommending digital rectal examination
yearly in all individuals over age 40, a stool blood test for occult
bleeding is recommended yearly and a proctoscopic examination
every 3-5 years after age 50.
Surgery alone is highly curative in the early stages, but when
there is regional nodal spread and/or deeply invasive tumors,
combined results with combined adjunctive radiation therapy and
chemotherapy have led to improved results in rectal lesions, and,
most recently, systemic treatment has resulted in improved
survivals in patients with lesions presenting at a higher level.
Although the number of patients in our review are limited, trends
for improved survival are noted in patients with local and regional
disease occurring between the studies. This may be in part due to
an increasing percentage of patients receiving combined treatment.
In spite of patients in 1983 presenting with a slightly increased
frequency of regional spread, the overall survival of patients was
still improved.
At this time early identification of patients with colorectal cancer,
particularly in known high risk groups, as well as possible
prevention through dietary changes with colorectal cancer is the
key in improving the outlook for patients with colorectal cancer.
Marcia J.S. Richards, M.D.
Chair
Cancer Committee
.

.

Marcia JS. Richards, M.D.
.
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It has been estimated that as many as 35% of
cancer deaths may be attributed to dietary
habits. The prevention of colon cancer by
changing dietary habits is a worthwhile goal
and may save lives. The National Cancer Insti
tute would like us to reduce average consump
tion of fat from 40% to 25% or less of total
calories by the year 2000. Recent research in\•
dicates that high fat diets may increase the risk
of developing colon cancer. However, research
has not supported the theory that high fiber
Sharon Thompson, RD.
diets will help to prevent colon cancer. A 1987
New York study of approximately 500 colon cancer cases showed
an almost two-fold increase in risk with a high fat intake but no
difference in risk for a high dietary fiber intake.
Advice to reduce the fat content of our diets is being promoted by
both national cancer and heart organizations. The American diet,
and more specifically the Midwestern diet, can benefit from some
recommended changes which are consistent with good health.
Reducing the fat content of our diets by using low fat dairy
products, choosing lean meats, fish and poultry, using a minimum
of fats and oils in the cooking process, limiting gravies and
sauces and cutting down on high fat desserts will help us make
the necessary changes in our dietary habits.
Sharon Thompson, R.D.

Prevention with Diet

Cancer of the colon and rectum represents a
serious health threat in the United States. It is
second only to lung cancer for incidence in
this country, involving nearly 150,000 new
cases a year. Approximately 60,000 to 70,000
deaths each year will be as a result of
metastatic colon carcinoma. The lifetime prob
ability of developing colorectal cancer in individuals with no additional risk factors is
approximately 5%.
Robert Taylor M.D.
Early detection of colon cancer has long been
viewed as an important step in reducing the morbidity and
mortality of this disease. This theory is based on solid data
suggesting that survival is directly related to the stage of the disease
with the best prognosis being observed in patients discovered early
and the worst in those discovered late. And while prevention of
colon cancer must ultimately be a goal, a more short term goal
of early detection will doubtless save thousands of lives.

Early Detection and
Screening of Colon Cancer

.

t
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Early Detection
(cotiued)

Dr. Robert Taylor explains to channel
12 announcer Tom Andrews a simple
method to detect early colon cancer in
patients without symptoms. The stool
blood slide is tested for hidden blood in
the feces.

In deciding who would benefit from screening programs for colon
cancer, one must understand who is at risk for this disease. It is
well known that the incidence of colon cancer rises sharply after
age 40, more sharply after age 50, doubling thereafter with each
decade. Patients who have had prior colorectal cancer have a
higher risk of recurrent disease. Those individuals who have
certain types of colonic polyposis may be at higher risk for
developing colon carcinoma subsequently. Patients with Gardner’s
syndrome, Peutz-Jegher’s syndrome and the familial cancer
syndrome must be considered at high risk. Finally, underlying
ulcerative colitis has long been known to be a risk factor for
colorectal cancer. Approximately a thousand new cases of colorec
tal cancer a year are discovered in this group of patients. The
longer the history of the disease and the more of the bowel that
is involved in the disease, the higher the risk for developing
subsequent colon carcinoma.
After identifying those groups at risk, one must choose the tests
for screening which are most likely to yield a low rate of false
positives and false negatives. To date, there have been 3 major
modalities used to screen for colorectal cancer. The first is the
digital rectal examination with or without occult blood testing of
the stool. At one time, it was thought that nearly three-quarters
of colon cancers were within the reach of an examining finger.
Current data, however, would suggest that only about a quarter
of them occur within the reach of the examining finger, less than
10% are detectable (palpable) by digital exam. Thus, digital rectal
examination seems to be a low-yield procedure for the discovery
of early colon and rectal cancers.
Sigmoidoscopy has also been used as a tool for evaluating early
colon cancer. With a flexible sigmoidoscope, the entire rectosig
moid can be examined, allowing evaluation of an area where
55% of cancers and adenomas occur. Unfortunately, the effectiveness of sigmoidoscopy as a screening tool has not been well
studied. In a study by Memorial Sloan-Kettering Cancer Center, a
screening program of using rigid sigmoidoscopy detected 58
cancers in 47,000 patients screened. Of these, 81% were either
Dukes’ A or B lesions, and the 15-year survival in these patients
was 90% Other studies have produced similar results.
Unfortunately, this is a relatively expensive and time-consuming
test, and one that cannot be done effectively in large populations.
Its usefulness may lie in the evaluation of patients screened
through other techniques who need further evaluation.
Occult blood testing of the stool was first proposed in 1901 and
has become a widely-used tool for screening the intestinal tract
for malignant and non-malignant pathology. Many studies utilizing
occult blood testing techniques have been undertaken, including 4
large controlled trials. Several conclusions can be reached from
.
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these trials. First, the predictive value of this test for pre
malignant lesions and cancer is strongly dependent upon age,
with a poor predictive value for those patients under age 50. Sen
sitivity of the test in those patients over age 50 was estimated to
be approximately 70% and the specificity of the test, 98% It
was clear that patients whose tumors were discovered using the
occult blood testing has a much earlier stage than a comparable
control group whose tumors were discovered by other means.
Patients whose tumors were discovered on the first screening test
had a much higher incidence of true positives than those patients
who were tested on second and subsequent screenings. Obviously,
patient compliance and adherence to the pre-testing diet is essen
tial, and false positives in large series can be high if appropriate
instructions are not followed closely by the patient.
What then can we conclude about the best form of screening and
early detection for colorectal cancer? When all the modalities
above were tested on a cost-effective basis, it appears that the
most cost-effective screening program for large populations is an
annual stool blood test done with appropriate diet restrictions,
and either a flexible or rigid sigmoidoscopy every 5 years. While
not as sensitive as yearly sigmoidoscopy, the cost savings is
substantial and the difference in survival is relatively small in
comparison.
Occult blood testing is a simple and inexpensive tool for detecting
GI pathology. It can be especially useful in older patients and
those who will comply with a restricted diet. For large population
screening, it is the single most cost-effective method to detect
early disease. ft should be done on an annual basis.
Patients in extremely high-risk categories, as has been mentioned
earlier, require individualized approaches. When analyzed on a
cost-benefit basis, these patients would likely benefit from more
intensive study on a more regular basis. For example, colonoscopy
may be more appropriate in patients with inflammatory bowel
disease than flexible sigmoidoscopy. Additionally, in patients with
familial polyposis or other syndromes associated with multiple
colonic polyps, the colonoscope allows for removal of the poiyp at
the time of diagnosis, and thus would be a more cost-effective
approach.
,

.

In conclusion, screening for colorectal carcinoma has clear advan
tages in increasing early detection and improving survival. Careful
analysis of cost effectiveness and appropriate application of various
techniques to patients at higher risk must be applied when considering screening of large populations. When appropriate screening
methods are applied, however, it is clear that a substantial survival
benefit may be obtained. Ultimately, these survival benefits may
result in a substantial repayment of the cost of such screening.
Robert Taylor, M.D.
7

Early Detection
(continued)

COLON CANCER
STAGE DISTRIBUTION AT TIME OF DIAGNOSIS
1983 1988
(TOTAL CASES)
-

IN SITU
3.9%
UNKNOWN
.2%

\

1983
129 TOTAL CASES

\

ALL REGIONAL
38.8%

UNKNOWN
4.6%

REGIONAL
DIRECT
EXTENSION
29.4%

[

DISTANT
20.2°/c

\

REGIONAL
.%
TO LYMPH
REGIONAL BY
NODES
DIRECT EXTENSION 28%
AND LYMPH NODES
1O.1%

1988
109 TOTAL CASES

\
ALL REGIONAL
42.3%

STAGE Extent of disease determined at the time
of diagnosis and/or initial therapy.
IN SITU a tumor classifed microscopically as in
situ non-invasive, pre-invasive, non-infiltrating,
intraductal, intraepithelial or intraepidermal.
LOCAL neoplasm restricted to the organ of
origin, but may be invasive or infiltrating within the
organ of origin.
REGIONAL a tumor that has extended beyond
the limits of the organ of origin into (1) surrounding
organs or tissues by direct extension, (2) regional
lymph nodes by metastasis, or a combination of (1)
and (2) and appears to have spread no further.
DISTANT a neoplasm that has spread to other
organ or lymph nodes remote from the primary
tumor.
-

-

,

-

-

-

Colon Cancer:
The Role of Endoscopy
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Colorectal carcinoma is the second most
common cause of cancer death in the United
States. While there is controversy regarding
what procedures, if any, should be used to
screen the general population for colon carci
noma, there is agreement regarding recom
mendations for the population at high risk
for colon cancer. This population includes: a
family history of polyposis syndrome or col
on cancer, individuals with a sporadic
neoplastic polyp, prior colon cancer or
JUl’11 1. B7t)lk, I.I).
chronic inflammatory bowel disease.
Patients with a family history of a polyposis syndrome (familial
polyposis, Gardner’s syndrome, etc.) need to be screened for colon
polyps. Detection of adenomatous polyps (usually during
childhood) indicates the need to perform proctocolectomy to
prevent malignancy.
Sporadic adenomatous, villous or mixed colon polyps are
premalignant and the precursor of colon cancer. Any colon polyp
greater than 1/2 cm. should be completely removed and evaluated
histologically. Approximately 50% of individuals with an
adenomatous polyp will have other adenomas throughout the
colon and many with carcinoma of the colon will have associated
adenomatous polyps. After endoscopic removal of a benign
adenomatous polyp, follow up colonoscopy is indicated at one
year to be certain a metachronous polyp has not developed and
that the patient has a “clean” colon. After the colon has been
cleared of polyps, colonoscopy can be performed on a three year
interval to evaluate for recurrent polyps.
Endoscopic removal of in situ carcinoma within the head of a
polyp requires the same type of surveillance as a benign colon
polyp. Endoscopic removal of invasive carcinoma requires further
surgical resection for cure. In a patient who is not a candidate for
definitive surgical therapy, endoscopic follow up with cautery or
laser therapy may be performed every 3-6 months for palliation.
After surgical resection of a colorectal carcinoma, colonoscopic
surveillance is indicated. A suture line recurrence is felt to be
uncommon and thus recurrent colon cancer usually is outside of
the bowel wall. The importance of colonoscopy in patients with
colon cancer is to evaluate for either synchronous polyps or for
metachronous lesions. Ideally, complete colonoscopy should be
performed prior to a colon resection but if this is not possible
because of an obstructing carcinoma, colonoscopy can be
performed 3-6 months after surgery to remove any synchronous
polypoid lesions. Repeat colonoscopy is then indicated every 1-2
years to evaluate for formation of new polyps.

j//
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Patients with panulcerative colitis are at increased risk for carcino
ma after 10 years of disease whether it is active or inactive. The
early premalignant changes are categorized histologically from low
to high grade dysplasia. Annual surveillance colonoscopy with
multiple biopsies is mandatory in patients with chronic panulcera
tive colitis of 7-10 years duration to rule out dysplasia, and in
left-sided ulcerative colitis of 15-20 years duration. High grade
dysplastic changes are an indication for total colectomy because of
the high association of colon cancer.
Flexible sigmoidoscopy is a screening procedure for asymptomatic
adults over the age of 50 to detect and prevent rectosigmoid
carcinoma. Flexible sigmoidoscopy is not a substitute for total
colonoscopy in the surveillance of colon cancer or in high risk
patients. Polypoid lesions are not to be removed during flexible
sigmoidoscopy in patients whose colons are not adequately
cleansed because of the danger of explosion.
Endoscopic evaluation of the colon is indicated for detection of
carcinoma and colon polyps. The procedure may be therapeutic
in the prevention of carcinoma by removal of colon polyps or by
local control of carcinoma in patients who are not candidates for
definitive surgery.
John T. Bjork, M.D.
Chief, Section of Gastroenterology

You will be introduced to two new and excit
ing areas of colorectal surgery. The first is the
sphincter sparing procedure or coloanal
anastomosis. This may be accomplished with
either the direct coloanal procedure or with
the colo-pouchanal procedure. The second,
and perhaps more exciting, is the use of the
argon or neodymium:YAG laser for the pallia
tive treatment of colorectal cancer.
The most recent statistics provided by the
Terence V. Roth M.D.
American Cancer Society show that there will
be 151,000 cases of new colorectal cancer in 1989. The colon
accounting for 107,000 and the rectum for 44,000. In the state of
Wisconsin there will be 3 ,200 new cases of colorectal cancer.
Coloanal Anastomosis
This is the ultimate procedure to preserve the anal sphincters and
thus avoid permanent colostomy. However, it should not be
considered a substitute for the standard abdominoperineal
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Endoscopy
(coted)

COLON CANCER
AGE DISTRIBUTION AT TIME OF DIAGNOSIS
NOTE: THERE WERE NO PATIENTS
DIAGNOSED BEFORE 30 YRS OF AGE
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Surgery for
Colorectal Cancer

Colorectal Cancer Surgery
(cotze)

COLON CANCER
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FOR 1983 TO 1988
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NOTE: SINCE 1983, THERE IS AN INCREASED
TENDENCY TOWARD COMBINED TREATMENT
MODALITIES, NOTWITHSTANDING EARLIER
STAGE OF DISEASE.
PERCENTAGE OF PATIENTS RECEIVING
COMBINED TREATMENT
1983 = 28%
1988 = 35%
PERCENTAGE OF PATIENTS RECEIVING
SINGLE TREATMENT
1983 = 63%
1988 = 59%

resection for an extensive lower rectal carcinoma. Any procedure
must first completely remove the neoplasm along with the adjacent
lymph nodes, and second, preserve the sphincters to avoid the
need for a permanent colostomy and maintain adequate sphincter
function.
The stapling instruments available and the demonstration that
rectal carcinoma rarely extends distally beyond 1 cm, have resulted
in the feasibility of doing the sphincter saving procedure.
Upper third rectal carcinomas are amenable to anterior resection.
The middle third carcinomas may be resectable without the
sacrifice of the sphincters and the anal canal. Most carcinomas in
the lower third will require a standard abdominoperineal
resection.
The coloanal anastomosis may be accomplished directly or with a
J-shaped colo-pouchanal anastomosis. The latter is an attempt to
increase the reservoir capacity although not affecting stool
continence.
Indications for this procedure include the following:
Familial Polyposis
Middle third rectal carcinomas
Ulcerative rectocolitis
Adenoma
Stenosis of a very low
tumor
Villous
anterior resection
Radiation Proctitis
Carcinoid
Rectal fistula
Hirschsprung’s disease
Failed low anterior resection
Megarectum
Rectal Crohn’s
Contraindications for this procedure include the following:
Metastatic disease
High grain malignancy
Bulky pelvic tumor
Local spread to the sphincter complex
Advanced age (70) or debilitation
Acute inflammation in the area of surgery
Pre-existing impaired anal continence
Complications of this procedure include an anastomotic stricture
or anastomotic leak. Transient urinary retention may also occur
and pelvic sepsis is a possibility.
About 2/3 of the patients can discriminate stool from gas. The
cure rate is as good, in properly selected patients, as standard sur
gical therapy. There is little or no mortality and a low morbidity
associated with the procedure.

The Use of Laser in the Treatment of Neoplasms of the
Colorectum
of the new cases of colorectal cancer, a reported 8.5% 30%
are not resectable for cure at the time of the first diagnosis. The
-
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use of the laser for the palliation of obstruction and bleeding in
such cases has been reported as high as 97% successful. Two of
the available lasers which are useful for these procedures are the
argon and Nd:YAG (yttrium-aluminum-garnet). The argon laser
has a tissue penetration of 1mm and the Nd:YAG penetrates to
4mm. Therefore, the argon laser is used for superficial lesions
and the Nd:YAG is used for the deeper and more protuberant
lesions. The latter are first debulked with a loop before a laser is
used to ablate the tissue. The laser and a fiberoptic endoscope
can direct the energy to an anatomic site under precise visual
control. Sufficient heat is generated to coagulate, necrose or
vaporize the tissue. This procedure is an alternative to the use of
a diverting colostomy, radiation therapy, chemotherapy,
electrocoagulation and cryotherapy. The laser has the distinct
advantage over these procedures in that it can be done on an
ambulatory basis, there is no proctitis and little delayed
hemorrhage. It can be done above the peritoneal reflection, and it
may be repeated as often as necessary. The produre is done
without the need for spinal or general anesthesia which may be
important for some patients.
Indications for this procedure include the patient’s refusal of
surgery, serious medical problems and the extent of the tumor
with bleeding and/or obstruction. The laser may also be used for
the non-palliative situation. Of the 45% of colon cancer that
presents in the left colon, 10-15% present with obstruction. The
laser can be used to relieve that obstruction that would allow
preoperative preparation of the bowel. This would obviate the
need for a two or three stage procedure.
As with any procedure, there is a learning curve. The cecum does
not allow the margin of error that exists in the treatment of a
rectal lesion. There are certain complications that can occur.
There may be bleeding, fistula formation, perforation, abcess, and
when it fails, in a small percent of cases, a colostomy would be
required to relieve the obstruction. Patients can die from the cornplications. However, considering the patients that become
candidates for this procedure, laser therapy appears to meet the
standards of a good palliative procedure in patients who will
survive less than 15 months. The use of the laser for curative
intent, except as noted above for the preoperative relief of
obstruction, remains a future possibility. The limiting factor being
more accurate staging techniques which are not available at the
present.
Terence V. Roth, M.D.
Department of Surgery

11

Colorectal Cancer Surgery
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Post Operative Radiation Therapy
for Rectal Carcinoma

A wide variety of radiotherapy methods
are used at St. Luke’s Medical Center to
help treat colon cancer. Pre-operative,
intra-operative, post-operative and
palliative radiotherapy are all offered.

Co1orecta carcinoma is second only to lung
cancer as the leading cause of cancer deaths
in the United States. Surgery is the primary
treatment but radiotherapy is useful.
The most common application is in the postoperative adjuvant setting in which the
patient has been adequately surgically staged.
Those patients with high risk factors for local
regional or distant failure would be recom
mended to receive adjuvant therapy. This
Mitchell Pincus, M.D.
would include patients with positive lymph
nodes and/or patients with tumor infiltration
through the rectal wall or both. Using the so-called Astler-Collier
modification of the original Duke’s staging, this would include
patients with Stage B2, Cl or C2 disease. These patients are at a
very high risk for local regional failure; multiple institutional
studies have shown improvement in local regional control and
improvement in survival with post-operative pelvic irradiation.
Indeed, the most publicized randomized study from the G.I.
tumor study group showed the most benefit from the group of
patients that received both chemotherapy and radiation therapy. In
fact, this showed a statistically significant improvement in the
survival.
Here at St. Luke’s these high risk patients are either entered on
one of the national protocols or treated in the following fashion:
pelvic irradiation is begun as soon as the patient recovers from
the operation and 5FU chemotherapy is given concurrently usually
during the first three days and last three days of the radiation
therapy using F! bolus technique. In general, this is very well
tolerated by the patient and can be done all as an out-patient
receiving the chemotherapy at the Vince Lombardi Cancer Clinic
prior to coming to the out-patient Radiation Oncology Department for the actual radiation treatment. Depending on the original
stage of the patient, the post-operative radiation can decrease local
regional recurrence from 30 to 70% down to a 10 to 25% range.
Whether or not improved local regional control in itself will
benefit local regional failure in rectal carcinoma is a very important
goal as these patients are a very difficult management problem,
particularly with intractable pain when they recur.
Mitchell Pincus, M.D.
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Patients who are found to have apparently
localized colorectal cancer are managed with
surgical resection. Unfortunately many of these
patients leave the operating room with
undetectable deposits of residual disease which
eventually become clinically apparent as local,
regional or distant metastasis. The median
survival from the diagnosis metastatic disease
is 6 to 8 months. The challenge for
chemotherapy is to eradicate these small
deposits of cancer that remain post-operatively
Ronald Hart, \1.D.
and thereby increase survival.
Based on the reasoning that drugs found capable of decreasing
large nodules of metastatic disease would be prime candidates for
use in the post-op setting, the search for effective chemotherapy
programs began in patients with measurable metastatic disease.
These studies identified three effective chemotherapy drugs:
5 ftuoro-uracil, mitomycin C and the chlorethlynitrosoureas
(BCNU, CCNU, and Methyl-CCNU). Treatment with these drugs
lead to major tumor shrinkage in approximately 20% of patients,
but complete regressions of tumor were extremely rare. When
tested in the post-operative patients, a very slight delay in tumor
recurrence rate was seen, but this was clinically and statistically
insignificant. There was a clear need to develop more potent
chemotherapy before expecting any substantial improvement in
post-operative survival.
Recent efforts have concentrated on increasing the effectiveness of
5 Fluoro-uradil. This drug is a chemical analogue of the nutrient
uracil. It is sufficiently similar to uracil to be incorporated into
the pyrimidine metabolic pathways where it interferes with RNA
and DNA synthesis. With the expectation of increasing 5 FU’s
effectiveness, other pyrimidine active drugs were combined with
5 FU. Although the combinations were more effective at killing
colon cancer cells, in clinical trials they proved to be excessively
toxic, and there was no net improvement in the therapeutic index.
There was, however, one exception. Leucovorin, when combined
with 5 FU lead to a million fold increase in affinity to the target
enzyme thymidylate synthetase, a substantial increase in cancer
killing potency and only a modest increase in clinical toxicity. At
least 3 randomized trials have now shown that 5 FU-leucovorin is
superior to 5 FU alone in patients with advanced disease.
Other efforts to improve the effectiveness of 5 FU have focused
on the pharmacokinetics of the drug. The drug disappears from
the circulation with a half life of 10 minutes. Active intracellular
metabolites have prolonged half lives which vary among tissues.
In the earliest trials, 5 FU was given as an intravenous bolus,
either daily for 5 days or repeated weekly. ft was found that by
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Chemotherapy of
Colorectal Cancer

\
The newest modalities of care are
delivered with compassion and
understanding.

Colorectal Cancer Chemotherapy
(continued)

Clinical Trials in
Colorectal Cancer

prolonging the period of intravenous injection from a bolus to a
continuous 24 hour or 120 hour infusion, the drug was no
longer myelosuppressive, but there was an increase in mucosal
toxicity. Trials of very prolonged continuous infusions of 3
months duration have been found to be very well tolerated and
significantly more effective than bolus injections of 5 FU.
A third approach to improve the usefulness of 5 FU was to com
bine 5 FU with agents which can enhance the intrinsic immune
response. Levamisole, a drug with antiparasitic activity, has been
shown to stimulate immune responses, particularly depressed
T-cell activity. Treatment with levamisole results in increased antibody production, increased delayed hypersensitivity and increased
phagocytosis. The drug has little if any anti-tumor activity by
itself, but when given together with 5 FU in patients with resected
colon carcinoma, there was a very significant decrease in
recurrences, and an improvement in overall survival.
Armed with these more effective chemotherapy programs, large
scale clinical trials are now in progress to test the value of these
treatments when given to patients with resected colorectal cancer.
For colon carcinoma, the trials are designed to directly compare
the usefulness of 5 FU combined with leucovorin or levamisole
and will help define the optimal dose and schedule for postoperative chemotherapy. For rectal cancer, the trials are evaluating
the impact of infusional 5 FU compared to more conventional
bolus administration of 5 FU, and will define the contribution of
Methyl CCNU to the outcome of these patients.
Preliminary results from these adjuvant chemotherapy trials indicate
an improvement in disease free survival of 33% when compared
with patients treated with surgery alone. Since over 150,000
Americans develop colorectal cancer each year, the socio-economic
impact of this improvement is very large. It therefore becomes
critically important to rapidly confirm the effectiveness of these
treatments and to encourage widespread use of optimal therapy
for our patients with colorectal cancer.
Ronald Hart, M.D.

Recent adjuvant studies of colorectal cancer have shown a signifi
cant improvement in disease control and disease free survival.
These developments have received a great deal of media coverage
and many of your patients may be asking how they can receive
such treatments or participate in the on-going trials. However,
patients are frequently disappointed to find that they are not
eligible to receive these treatments because their surgery did not
meet the strict criteria specified in the clinical trial. The following
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is a compilation of operative techniques and operative note
documentation that is required by the current clinical trials. By
including these aspects in the medical record of your patients with
resectable colorectal cancer, your patients will have the option of
participating in these national clinical trials.
Common To All Trials
. State that the abdomen was explored to rule out metastatic
disease and mention negative as well as positive findings.
. State that the entire liver was visualized.
. Describe extent of extra-rectal or extra colonic extention
(lesion extends beyond the posterior rectal wall for approxi
mately 1 cm with cm of uninvolved perirectal fat).
. Note the level at which vessels were ligated and clipped (i.e.,
inferior mesenteric was ligated below the origin of the left
colic vessels).
. Note areas of adherence of tumor, mark resected specimen
with a clip at areas of adherence and obtain a biopsy of
unresected tissue at areas of adherence.
Rectal Cancer Trials
. Clip Placement. As many patients undergo surgery after a
colonoscopy and biopsy, and without a barium enema, it
can be very difficult to localize the initial tumor site for the
radiation boost field. It is therefore very important to either
perform a pre-operative imaging study (BE or CT) to define
tumor location or to leave surgical clips at the tumor bed as
a radiation marker. Use small vascular clips to mark areas of
tumor adherence and place large hemoclip at proximal extent
of vascular ligature to define nodal volumes for potential
irradiation.
. Pelvic Reconstruction. Since these trials are designed to
maximize the radiation dose which can be delivered safely,
any maneuvers to keep the small bowel out of the pelvis will
minimize the volume of small bowel irradiated. Possible techniques include reperitonealization of the pelvic floor, using
an omental sling, retroverting the uterus, etc.
. Specimen Marking. To assist the pathologist in defining
histologic margins, place a suture on the anterior rectal wall,
clip areas of adherence or areas of suspected narrow margins
and place a suture on the proximal extent of vascular liga
ture to define proximal nodes for sampling. (Obtain a biopsy
of unresected tissue at areas of adherence).
Ronald Hart, M.D.
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Clinical Trials
(continued)

Social Services

Learning to live with cancer presents extraordinary physical,
emotional and social challenges to the patients and their families.
The oncology social worker plays a vital role in helping the
patient and family deal with the practical concerns and stresses
involved. The overall goal of these efforts is the maximum
appropriate use of the health care system and the best possible
adaptation to illness by the patient within the values and
individual coping style of the individual patient and his/her
family.
‘

—.-

‘1
:
:

Oncology social worker, Grace
McCutcheon, aids patients and their
families to learn to live with cancer and
gain the best possible lifestyle.

By aiding the patient/family in resolution of financial, job-related
or other day-to-day problems, or by providing the opportunity to
talk out their questions and feelings, the oncology social worker
assists the entire family to mobilize their own inner coping
resources as well as the resources of the hospital and community.
For the last one-and-a-half years, one social worker has been
assigned primarily to the oncology program (in-patient unit and
one radiation and one medical oncology clinics). This reflects
both the growth of the program and its importance.
Specific services provided by the social worker include help with
governmental benefits delivery systems, financial problems, assessment of home situation, life-style changes related to illness,
disability or compliance with treatment, discharge planning, and
information and referral on a differential basis to community
agencies: facilitating the successful interaction between the patient
in the hospital, the family, and the larger environment.
All these tasks are performed within the context of the oncology
unit’s multidisciplinary team. Because of the acute nature of the
problems, short term crisis intervention is the most common treatment modality. However, as the patient/family return to the
hospital on many occasions for treatment of this chronic disease,
long-term relationships develop which sustain the work on multiple
issues and problems related to diagnosis, treatment, possible
relapse and continued treatment or death.
This year the oncology social worker also led the re-establishment
of the regional professional group for oncology social workers
and edits their quarterly newsletter. Involvement with the American
Cancer Society activities on a state level provides visibility for
St. Luke’s program and general information for social work.
Grace McCutcheon
Medical Social Worker
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Cancer of the Colorectum
Long and Short Term
Patient Care Evaluation Studies
American College of Surgeons
St. Luke’s participated in this national study in 1988. One of
the purposes of this study is to document changes in diagnostic
and clinical management of colon cancer in the United States.
We compared data from the present year, 198$, to five years
ago, 1983. Twenty five successive cases were chosen starting
with January of each year. All patients were diagnosed at St.
Luke’s and for the most part received their first course of therapy
here. All cases were required to have a positive histology of
adenocarcinoma.
Following are some of the more interesting comparisons. A history
of previous cancer was documented in only 4 patients in 1983
and 3 patients in 19$ 8.
Are there fewer recurrences?

No recurrence
Never disease free
Recurrence
Unknown
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1983
14 pts.
10 pts
1 pt.
0 pt.

1988
1$ pts.
6 pts.
0 Pt.
1 Pt.

Long and Short Term Study
(cotiue
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Long and Short Term Study
(continued)
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Long and Short Term Study

Is COLORECTAL CANCER
BEING DETECTED EARLIER
THAN FIVE YEARS AGO?

(cotie)

STAGE OF DISEASE AT DIAGNOSIS
1983 1988
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New Developments in 1988

This past year the Section
of Radiation Oncology in
cooperation with the
Department of Urology
have performed Milwaukee’s
first case of temporary
intersitial iridium implants
for patients with carcinoma
of the prostate. The program is designed for patients
with locally advanced
carcinoma of the prostate
(Bulky Stage B-TI and Stage
C) which generally is not
amenable to radical
prostatectomy and have a
moderately high incidence
of biopsy-proven residual
tumor after conventional
external beam radiation
therapy.
Over the last several years
Radiation Oncologists at St. Marcia J.S. Richards, M.D. Barry H. Usow, M.D.
Luke’s Medical Center have
developed a large experience with pelvic brachytherapy procedures
using afterloading iridium 192 with a template technique for patients
with cancer of the cervix, vagina and selected rectal cancers. The
advantage of the temporary afterloading technique over the more
commonly used permanent Iodine seed implants is there is no
unnecessary radiation exposure to operating room personnel and
improved control over the distribution of radiation.
The patient undergoes a bilateral pelvic lymphadenectomy followed
by an Iridium implant to deliver 3000-3500 cGy in four days. The
patient goes home on the fifth postoperative day and following the
implant usually receives an additional 3000-4000 cGy with
conventional external beam radiation therapy.
The use of this technique has been demonstrated at other institutions
to have extremely low risk of complications and has shown improved
local control, biopsy-proven, of locally advanced disease. To date five
patients beginning in November, 1988, have been treated under the
current protocol, all of whom had tolerated the procedure well and
shown local tumor control at this early date. We believe that
interstitial iridium implants of the prostate will compliment the
ongoing Brachytherapy Program and will continue to play an
important role in the treatment of locally advanced cancers.
Howard J. Lewis, M.D.
Samuel J. Otto, M.D.
Marcia J.S. Richards, M.D.
Barry H. Usow, M.D.
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Indium Implants of the Prostate

Insertion of radioactive implants in
patients with localized prostatic cancer
may increase their chances of local
control and long term survival.

Immunotherapy Program
(formerly LAX LAB)

Immunotherapy has joined surgery, radiation
therapy and chemotherapy as an important
weapon in the war against cancer and offers
additional hope for today’s cancer patients
and tremendous promise for the future.
Immunotherapy treatments employ natural
stimulants of the anti-cancer arm of the
immune system such as the interleukins and
interferons as well as highly activated special
white blood cells that destroy cancer cells
without harming normal ones. The latest
Robert Petit, Ph.D.
developments from biotechnology are available
today through St. Luke’s pioneering, state-of-the-art program.
The Immunotherapy Program has provided over 35 courses of
IL-2/LAK treatment for patients with melanoma, kidney cancer,
refractory lymphoma, cardnoid tumor, and cancers of the lung,
liver, pancreas, colon and biliary tract. Immunotherapy is now
standard treatment for malignant melanoma and kidney cancer
and is most effective when delivered early in the course of the
disease. The program now offers several types of Immunotherapy:
IL-2/LAK therapy, TIL therapy, Interferon and H2 antagonists,
and the combination immunotherapies of Interferon and
IL-2/LAK, and Interferon and IL-2.
The Immunotherapy Program will be supported by a new
immunology research laboratory in the coming year. This lab will
employ novel biological tools to develop new and improved
immunotherapies and provide scientific leads that can translate
into clinical responses and offer additional hope.
Immunotherapy Program treatments are sponsored by the National
Cancer Institute, major drug companies and medical science experts
at St. Luke’s. All of our treatments are approved by the FDA.
Immunotherapy is now available for all types of tumors. Our
program is dedicated to the development of this promising
technology and to providing the best cancer therapy available
anywhere to the people of the southeast Wisconsin area. Cancer
will soon become the number one killer of Americans. St. Luke’s
is meeting the challenge of cancer by becoming a leader in the
development of powerful new weapons and fighting with these
weapons in the front lines of the war against cancer.
Robert Petit, Ph.D.
.
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Virginia (Ginny) Bourne, Clinical Nurse
Specialist in Thanatology at St. Luke’s Medical
Center was selected as one of 21 nurses in the
United States to receive the Lane W. Adams
Award presented by the American Cancer
Society. As the American Cancer Society states,
“The objective of the Lane W. Adams Award
for 1989 is to recognize and reward individual
nurses whose practice has been characterized
by consistent excellence in providing compas
sionate, skilled care to persons with cancer
Sally DeVilend, RN
and counsel to their families.” The concept of
the “warm hand of service” was given special emphasis by Lane
w. Adams when he served as Executive Vice-President of the
American Cancer Society. The award for 1989 focused on nurses
providing care in a variety of settings and recognized the
importance of the critical role nurses provide in direct cancer care.
Ginny and the other award recipients were recognized at a special
ceremony at the Waldorf Astoria Hotel in New York City in
conjunction with the American Cancer Society’s National Board
of Directors meeting on March 3, 1989.
Ginny was nominated for the award by a staff nurse at St. Luke’s,
and her nomination was supported by two fellow nurses and two
family members of patients whom she had provided support.
Ginny was supported in her nomination for her “warm hand of
service” to patients at St. Luke’s and to the community at large
through the American Cancer Society.
She was fundamental in establishing the “Caring Connection’ a
cancer support group, at St. Luke’s. The “Caring Connection”
meets twice a month and Ginny serves as a facilitator for the
group. She has also established support groups through the
American Cancer Society for which she serves as a facilitator.
She meets with newly diagnosed cancer patients to help them
cope with the changes in their lives that the diagnosis of cancer
can bring. She may see the patients at various times throughout
their illness. She assists the patient and family during the terminal
phase of the illness to allow a dignified and comfortable death.
Ginny also lends support and guidance to the nursing staff in
caring for the terminally ill. Ginny has lectured extensively on the
care of the terminally ill, and is nationally known for her effort.
She has demonstrated excellence in delivering patient care and
serves as a role model for other nurses.
Sally DeVriend, RN
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Nursing Focus
Virginia Boume
Lane W. Adams Award Recepient
-

Ginny Bourne, recipient of the Lane W.
Adams award for excellence in nursing,
is pictured with Greg Fecteau, Director
of Oncology Services.

Cancer Rejstry Report

A highlight of our cancer program was the survey by the
American College of Surgeons. We were granted three year
approval again, with special regards to the outpatient oncology
department. This survey is voluntary and measures the efforts of
a hospital cancer program to provide optimal patient care.
Essential program elements are quality control and audits,
education, multidisciplinary exchange and monitoring of
treatment through successful long term patient follow-up. Our
follow-up at survey time was 99%.
Our registry has been in existence since 1960, with over 14,000
total patients. In 1988, 1,195 new patients were accessioned into
the registry: 1,008 analytic, 187 non-analytic.
Kathy Bielinski
Cancer Registrar

1988 ALL SITES DISTRIBUTED BY STAGE
NOTE: IN SITU AND LOCAL STAGES MAKE UP 46.3% OF
THE PATIENTS DIAGNOSED. EARLY DETECTION OF
CANCER CONTRIBUTES SIGNIFICANTLY TO LONG
TERM SURVIVAL.
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REGIONAL DIRECT
EXTENSION
1 2.8%
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LYMPH
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-

Cancer Registry Report
(cotie)
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St. Luke’s Cancer Conferences

Tumor Board Conference

Head and Neck Tumor Conference

Security Savings & Loan Cancer
Lectureship Series 1988

Conferences are held on the second and fourth Monday of every
month at noon. This is a patient oriented, multi-disciplinary
cancer conference. For more information or questions, please call
649-6225.
This is a conference to discuss selected difficult head and neck
tumors from a multi-disciplinary approach. Conferences are held
on the first and third Monday of every month at noon. For more
information or questions, please call 649-3900.
January 21, 1988
IMPACT OF AIDS ON NEUROLOGY AND NEUROSURGERY
Mark L. Rosenbium, M.D.
Associate Professor of Neurosurgery
University of California Medical School, San Francisco, CA
March 10, 1988
TESTICULAR CANCER: EVOLVING ThERAPEUTIC
OPTIONS IN THE 1980’S
Jerome P. Richie, M.D.
Elliott C. Cutler Professor of Urologic Surgery
Harvard Medical School
Chief of Urology
Brigham & Women’s Hospital, Boston, MA
March 31, 1988
RECENT ADVANCES N ThE TREATMENT OF
SUPERFICIAL AND ADVANCED BLADDER CA AT
STANFORD
Frank M. Toni, M.D.
Associate Professor Medicine
Division of Medical Oncology
Chief of Urology
Stanford University Medical Center, Stanford, CA
April 21, 1988
COMBINED CHEMOTHERAPY AND RADIATION ThERAPY
FOR PATIENTS WITh MUSCLE-INVADING BLADDER
CARCINOMA: A PRELIMINARY REPORT OF A BLADDER
SPARING EFFORT
William U. Shipley, M.D.
Associate Professor Radiotherapy
Harvard Medical School, Boston, MA
May 19, 1988
CURRENT MANAGEMENT OF PROSTATE CANCER
Marc B. Garnick, M.D.
Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute, Boston, MA
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7, 1988
NEW APPROACHES TO ThE IMMUNOTHERAPY
Of CANCER
Steven Rosenberg, M.D.
Chief of Surgery Branch
National Cancer Institute, Bethesda, MD
July 28, 1988
IRRADIATION Of PROSTATIC CANCER TECHMQUE
AND RESULTS
Malcolm A. Bagshaw, M.D.
Catharine & Howard Avery Professor
Chairman, Dept. of Therapeutic Radiology
Director, Division of Radiation Therapy
Stanford University School of Medicine, Stanford, CA
October 27, 1988
NEW ThERAPIES FOR BLADDER CANCER
Alan Yagoda, M.D.
Professor Clinical Medicine
Cornell University Medical College
New York, NY
Acting Chief
Solid Tumor Service, Department of Medicine
Memorial Sloan-Kettering Cancer Center, New York, NY
November 10, 1988
LABORATORY AND CLINICAL EXPERIENCE IN
INTRAOPERATIVE RADIATION
Timothy J. Kinsella, M.D.
Professor and Chairman
Department of Human Oncology
University of Wisconsin Medical School, Madison, WI
Deputy Director,
University of Wisconsin Clinical Cancer Center, Madison, WI
December 8, 1988
TREATMENT Of SUPERHCIAL AND INVASIVE BLADDER
CANCER INCLUDING CYSTECTOMY AND A
CONTINENT URINARY RESERVOIR
Randall G. Rowland, M.D.
Associate Professor and Director of Research
Department of Urology
Indiana University School of Medicine, Indianapolis, IN
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St. Luke’s Cancer Conferences
(continued)

Glossary

Stage Extent of disease determined at the time of diagnosis
and/or initial therapy.
IN SITU a tumor classified microscopically as in situ, noninvasive, pre-invasive, non-infiltrating, intraductal, intraepithelial
or intraepidermal.
LOCAL neoplasm restricted to the organ of origin, but may be
invasive or infiltrating within the organ of origin.
REGIONAL a tumor that has extended beyond the limits of
the organ of origin into (1) surrounding organs or tissues by
direct extension, (2) regional lymph nodes by metastasis, or a
combination of (1) and (2) and appears to have spread no
further.
DISTANT a neoplasm that has spread to other organs or
lymph nodes remote from the primary tumor.
-

-

-

-

-

First Course of Treatment The tumor directed treatments started
within the first four months after diagnosis.
ANALYTIC CASES Cases which are first diagnosed and/or
given their first course of treatment at St. Luke’s Medical
Center.
NON-ANALYTIC CASES Cases which are seen at St. Luke’s
Medical Center after the first course of treatment and those
cases where the patient is diagnosed at autopsy.
-

-

-

Treatment
SURGERY the partial or total removal of the tumor excluding
biopsy.
RADIATION cancer-related beam and non-beam therapy (non
beam includes radium, cesium and radioactive isotopes).
CHEMOTHERAPY treatment of cancer using drugs.
COMBINED THERAPY refers to any combination of surgery,
radiation, chemotherapy, hormone therapy or other therapy
administered jointly as a single course of treatment.
DIAGNOSTIC ONLY cancer-related treatment not given; this
may occur for many reasons; for example, patient refused
treatment, diagnosed at autopsy, or the patient’s general
condition is unsatisfactory for treatment.
-

-

-

-

-
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“The quality of each man’s life is in the full measure of
that mans personal commitment to excellence and to victory.”
Vince Lombardi

